Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Study of RSV Vaccine Candidate in Adults
NCT05639894Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2022
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised trial in respiratory syncytial virus infection (RSV) (17 arms), sponsored by Sanofi. Primary endpoints: Number of Participants With Immediate Unsolicited Systemic Adverse Events, Number of Participants With Solicited Injection Site Reactions and Systemic Reactions and 6 more. Started Nov 2022; status: completed.
02
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05639894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639894.